Jordane is a molecular biologist and neuroscientist specializing in genomics, with over 15 years of research experience. Prior to joining Regel, Jordane was a Group Leader at the Broad Institute of MIT and Harvard, where his team developed novel approaches to de-risk the use of gene therapy vectors. His research, which now constitutes a core component of Regel’s pipeline, focused on improving the safety and efficacy of viral vectors by restricting their action exclusively to the cells affected by disease. Jordane received his Ph.D. in Molecular and Cellular Neuroscience from the University of Brussels and completed his postdoctoral training in the laboratory of Dr. Fishell at the NYU School of Medicine and Harvard Medical School.

Navneet is a molecular biologist specialized in genetics and genomics with 18 years of research experience. She was a Principal Investigator at the Innovative Genomics Institute and Assistant Professor at UCSF. Her research focus has been on exploring regulatory elements of the genome and utilizing them as therapeutic targets for gene modulation. She has pioneered the use of non-editing CRISPR based platforms as a therapeutic modality for treating dosage sensitive diseases. Navneet is the winner of the Charles, J Epstein award for Excellence in Human Genetic Research, American Society for Human Genetics 2017. She received her Ph.D in Molecular & Cellular Biology from the Jawaharlal Nehru University, Center for Cellular and Molecular Biology, India and completed her postdoctoral training in the laboratory of Dr. Ahituv at University of California San Francisco.

Michael has over 15 years of experience in healthcare investment research and asset management. He is an advisor to HBM Partners, a leading healthcare focused investment fund. Previously, Michael was the biotech analyst for Traxis Partners, Sivik Global Healthcare and Jefferies Asset Management. Michael has also been a founder of several development stage biotech companies and presently serves on 4 company boards. Michael received a Master’s degree in Medical Science from MCP/Hahnemann School of Medicine and has worked in R&D for SmithKline Beecham Pharmaceuticals.

Dr. Andrew Schiermeier has spent over two decades as an executive in the biotech and pharmaceutical sectors, with experience from managing operations for startups to leading the strategic expansion of global brands, including Intellia Therapeutics, Merck KGaA, Aura Biosciences, and Medicine in Need. Andrew is currently the President & CEO of AvenCell Therapeutics, a clinical-stage Cambridge, MA and Dresden, Germany-based biotech that develops industry-leading CAR-T cell therapies. Andrew holds a Ph.D. in Applied Mathematics from Harvard University, an M.S. in Biomechanical Engineering from Stanford University, a B.S. in Mechanical Engineering from Washington University in St. Louis, and an International MBA from College des Ingenieurs in Paris, France.

Megan has over 10 years of experience across healthcare including clinical medicine, research, management consulting and drug development. She received a BA, magna cum laude, from the University of Pennsylvania in neuroscience, chemistry and music. She completed her MD and PhD degrees at New York University with a PhD in neuroimaging and MRI physics, and was elected to Alpha Omega Alpha Honor Medical Society. Megan trained as a radiologist at NYU Langone Medical Center and previously held roles at McKinsey & Co. in the firm’s healthcare practice, Regenxbio, a gene therapy company and BridgeBio, a genetic disease company. In addition to her current role of interim CEO at Regel, Megan is also the CEO of Epitor Therapeutics (epigenetic editing) and HitchBio (red blood cell drug delivery).

Orrin is a renowned epilepsy neurologist who directs the NYU Epilepsy Center. He has published more than 500 peer reviewed articles and written or edited more than 20 books on neurological, psychiatric, neurosurgical, cognitive, and basic science topics. He has served on the scientific advisory board for more than 12 rare genetic disorder organizations and is involved in several gene therapy/molecular biology startups. His research led to the first FDA approval of a cannabinoid medication, cannabidiol, and he has also been studied leading to the approval of more than 10 other medications and neuromodulatory devices.

Nadav is a Professor in the Department of Bioengineering and Therapeutic Sciences and the interim director of the Institute for Human Genetics at the University of California, San Francisco. He received his PhD in human genetics from Tel-Aviv University working on hereditary hearing loss. He then did his postdoc, specializing in functional genomics, in the Lawrence Berkeley National Laboratory and the DOE Joint Genome Institute in Rubin’s lab. His lab is focused on identifying gene regulatory elements and linking nucleotide variation within them to various phenotypes including drug response and human disease. In addition, his lab develops and uses massively parallel reporter assays (MPRAs) that allow for high-throughput functional characterization of gene regulatory elements and the use of gene regulatory elements as therapeutic targets and diagnostics.

Wendy is a clinical and molecular geneticist and the Kennedy Family Professor of Pediatrics and Medicine and Director of Clinical Genetics at Columbia University. She received her B.A. in biochemistry and economics from Cornell University, her M.D. from Cornell University Medical College, and her Ph.D. from The Rockefeller University in genetics. Dr. Chung has identified over 50 genes for pulmonary hypertension, autism, neurodevelopmental disorders, and birth defects including congenital diaphragmatic hernia and congenital heart disease and has characterized the molecular defects and natural history of many of these rare genetic diseases. She leads the Precision Medicine Resource in the Irving Institute at Columbia University. She was the recipient of the Medical Achievement Award from Bonei Olam, the NY Academy of Medicine Medal for Distinguished Contributions in Biomedical Science, the Rare Impact Award from the National Organization of Rare Disorders, and is a member of the National Academy of Medicine and the American Academy of Physicians.

Kevin, is an Associate Professor at UCSF in the Department of Neurology and holds an Endowed Chair in Honor of the Gallo Family. He and his lab have a long-standing interest in understanding and treating brain cells and circuits affected in neurodevelopmental and neuropsychiatric disease, with a particular focus on function and dysfunction of ion channels that mediate integration of information in the brain. He received his Ph.D in Biology from UCSD with Dr. Daniel Feldman and his postdoctoral training with Dr. Laurence Trussell at OHSU.

Having run a laboratory for 23 years and starting the NYU Neuroscience institute as its founding associate director, Gord moved his group to Harvard medical school and the Broad institute in 2017. His efforts to understand the molecular and circuit basis of inhibition have been broadly published in Nature, Science, Cell and Neuron. Presently, by combining single cell transcriptomics and systems neuroscience, his group seeks to understand both normal and path-physiological brain function.